Micrologix Biotech and Fujisawa Healthcare entered into a collaboration and licensing agreement to co-develop and commercialize Micrologix’s proprietary cationic peptide product candidate, MBI 226 useful for preventing CVC-related blood stream infections. The deal could be worth up to US$21 M.